NASDAQ
TARA

Protara Therapeutics Inc

(NO DISGNOSTIC SUBSTANCES)
LIFE SCIENCES

Prices are adjusted according to historical splits.

Protara Therapeutics Inc Stock Price

Vitals

Today's Low:
$2.9700
Today's High:
$3.0900
Open Price:
$3.0500
52W Low:
$2.72
52W High:
$7.97
Prev. Close:
$3.0900
Volume:
17733

Company Statistics

Market Cap.:
$0.033 billion
Book Value:
12.92
Revenue TTM:
$0.000 billion
Operating Margin TTM:
0%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-14.8%
Return on Equity TTM:
-24.9%

Company Profile

Protara Therapeutics Inc had its IPO on 2014-10-22 under the ticker symbol TARA.

The company operates in the LIFE SCIENCES sector and (NO DISGNOSTIC SUBSTANCES) industry. Protara Therapeutics Inc has a staff strength of 0 employees.

Stock update

Shares of Protara Therapeutics Inc opened at $3.05 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $2.97 - $3.09, and closed at $2.97.

This is a -3.88% slip from the previous day's closing price.

A total volume of 17,733 shares were traded at the close of the day’s session.

In the last one week, shares of Protara Therapeutics Inc have slipped by -1%.

Protara Therapeutics Inc's Key Ratios

Protara Therapeutics Inc has a market cap of $0.033 billion, indicating a price to book ratio of 0.249 and a price to sales ratio of -.

In the last 12-months Protara Therapeutics Inc’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.041 billion. The EBITDA ratio measures Protara Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Protara Therapeutics Inc’s operating margin was 0% while its return on assets stood at -14.8% with a return of equity of -24.9%.

In Q2, Protara Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Protara Therapeutics Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
None

Its diluted EPS in the last 12-months stands at $-3.963 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Protara Therapeutics Inc’s profitability.

Protara Therapeutics Inc stock is trading at a EV to sales ratio of - and a EV to EBITDA ratio of 1.443. Its price to sales ratio in the trailing 12-months stood at -.

Protara Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Protara Therapeutics Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Protara Therapeutics Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Protara Therapeutics Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Protara Therapeutics Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Protara Therapeutics Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$2.97
52-Week High
$7.97
52-Week Low
$2.72
Analyst Target Price
$33.75

Protara Therapeutics Inc stock is currently trading at $2.97 per share. It touched a 52-week high of $7.97 and a 52-week low of $7.97. Analysts tracking the stock have a 12-month average target price of $33.75.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Protara Therapeutics Inc

The stock symbol (also called stock or share ticker) of Protara Therapeutics Inc is TARA

The IPO of Protara Therapeutics Inc took place on 2014-10-22

Similar Industry Stocks ((NO DISGNOSTIC SUBSTANCES))

Last Price
Chg
Chg%
$1.25
0.03
+2.46%
$3.51
-0.04
-1.13%
$2.78
-0.13
-4.47%
$2.84
-0.08
-2.74%
$20.01
0
0%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
$0.02
0.01
+100%
Oi S.A (OIBR-C)
$0
0
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare diseases. The company is headquartered in New York, New York.

Address

200 WEST STREET, WALTHAM, MA, US